Valeant Fire Sale -- Value Play?

Valeant is down 20% today on missed earnings, slashed guidance, and is trading a few bucks off of its book value, and something like 4x forward earnings.

There are some interesting articles floating around, posturing that the value of the underlying Valeant businesses is greater than Valeant's current market cap.

What do you guys think about investing in this company as a pure value play? I'd love to hear some original thoughts/opinions.

7 Comments
 
Best Response

Personally I would never label a company like Valeant as a "value play", regardless of how cheap it gets. Just because a company trades at a significant discount to its historical valuation doesn't mean it's a good buy-- in fact, these are exactly the value traps you should look out for. Instead, a restructuring/activist play is likely the only way this company's stock will see a rebound.

Ackman's back is against the wall, and with increasing scrutiny placed on big pharma these days alongside the heaps of debt the company acquired through inorganic growth, he's going to have a tough time digging himself out of this one. The reason why Valeant will never be a value play in my eyes is shady accounting practices, uncertainty of management moving forward and I honestly don't see this Valeant's price gouging to be sustainable given the publicity Clinton/Shkreli/et al has brought upon over the last year or so. Perhaps Valeant could be a good speculative play if you have an opinion on a price floor for the company's stock, but I can see this stock either going to 0 or rallying 100-200%. Personally staying out of this one myself.

 
"StreetofBulls"

Personally I would never label a company like Valeant as a "value play", regardless of how cheap it gets. Just because a company trades at a significant discount to its historical valuation doesn't mean it's a good buy-- in fact, these are exactly the value traps you should look out for. Instead, a restructuring/activist play is likely the only way this company's stock will see a rebound.

Ackman's back is against the wall, and with increasing scrutiny placed on big pharma these days alongside the heaps of debt the company acquired through inorganic growth, he's going to have a tough time digging himself out of this one. The reason why Valeant will never be a value play in my eyes is shady accounting practices, uncertainty of management moving forward and I honestly don't see this Valeant's price gouging to be sustainable given the publicity Clinton/Shkreli/et al has brought upon over the last year or so. Perhaps Valeant could be a good speculative play if you have an opinion on a price floor for the company's stock, but I can see this stock either going to 0 or rallying 100-200%. Personally staying out of this one myself.

I have read that at it's current valuation, there is a non-negligible chance that sometime in the future the company could potentially be an M&A target. This is because there are probably at least one or two good and extremely cheap businesses (haven't personally done the research) rolled up in Valeant.

I think that contingent upon either 1) long-term price rebound potential, or 2) possibility of being acquired, it could be an interesting buy and hold. I agree with you that it would probably teeter more into speculation than investing.

Career Advancement Opportunities

August 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.4%
  • Morgan Stanley 08 97.8%
  • Goldman Sachs 02 97.3%

Overall Employee Satisfaction

August 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Evercore No 98.9%
  • Morgan Stanley 01 98.4%
  • Banco Santander 02 97.8%
  • BMO Capital Markets 12 97.3%

Professional Growth Opportunities

August 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 07 98.4%
  • Goldman Sachs 01 97.8%
  • JPMorgan No 97.3%

Total Avg Compensation

August 2026 Investment Banking

  • Vice President (16) $429
  • Associates (50) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (25) $178
  • Intern/Summer Associate (14) $159
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (75) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”